The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates in treatment options for patients with AML
Rory Shallis, MD, Yale Cancer Center, West Haven, CT, shares his insights on treatment algorithms for patients with acute myeloid leukemia (AML), drawing focus on the decision-making process, including whether patients are eligible for intensive therapy, or would benefit from less intensive options. Dr Shallis then discusses the importance of considering disease biology when choosing treatment regimens, mentioning the impact of mutations such as FLT3, IDH1, and IDH2 in guiding this choice. To conclude, Dr Shallis mentions the importance of deciding whether a patient is eligible for allogeneic hematopoietic stem cell transplant (allo-HSCT) and how this may influence survival outcome. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
